george scangos, ceo of biogen, joining us in san francisco.ll ahead, meet one of the investors who is going to bet $300 million on dov charney. he says the founder was wrong and is working -- was wronged and is working to bring him back. he joins us after the break. ♪ desk: back to our markets where julie hyman has a check out some of the company movers as we are losing a little bit of ground. julie: i do want to check on oil in my bloomberg to mineral -- bloomberg terminal. what you are seeing here is the s&p 500 in white coming down as oil comes down a little more sharply. oil is giving up all of its gains. the s&p 500 is hanging onto a gain of about half of 1% but it is definitely paring it as we see oil come down. that is the correlation we have seen in recent days. just something to keep an eye on as we came out of the gate very strong and that we are not nearly as strong in terms of .ocs we are getting into cursing -- earnings season, and alcoa came out with the actual numbers after the close of trading. sales down 18%. to company had a

we have the ceo of biogen about his company's pipeline as you saw that sector today, bill, down 4.5%. we will talk to biogen coming up. >>> over the weekend protests in germany that could be very bad news for chancellor merkel. we have the details and the impact that angela merkel's vulnerability could have on the broader european economy. that's a o story we're watching carefully right now. >> oil hitting a fresh 12-year low today. jackie deangelis has the latest. >> as you said at the top of the show it was really interesting the way equities tried to take off today and oil dragged them back down. we saw 5% decline, 31.41 is where we finished the session but that was after we hit an intraday low of 30.88, a 12-year low. traders always telling me we test these lows before we brake and hold. it's not surprising as we approach that $30 mark we will probably going to break through it. what drove the losses today, this was all about china, multiple pieces of the story here. obviously a lot of people are worried about the demand side so they will be watching every data point that comes ou

with you. >> take a look at this versus the ibb, much more the larger cap biotech stocks and the biogen. >> which should be safer. >> which is not -- the xbi which is baxalta and others. so it's very different. >> you want to be in the big caps here. >> you want the ibb. >> want one or the other. >> what's the rather. >> >> ibb over the xbi. i think that's a case, who is selling netflix, the same people selling the ibb. >> coming up, facebook shares surging after smashing earning expectations. we'll hear from ceo mark zuckerberg on the blowout quarter in his own words. and las vegas sands and is there a bottom in for macau? here's what's coming up on "fast." ♪ oops i did it again >> that's what traders are saying about janet yellen and the fed and it's causing chaos in one crucial part of the market and something is happening to shares of tesla and it could spell trouble for investors. >> i couldn't live with my level. >> we'll tell you what it is when "fast money" returns. in new york state, we believe tomorrow starts today. all across the state the economy is growing, with creative ne

biogen has created near replica of the drug embren at plant in rhode island. europe allows the sale of these biosimilars and u.s. does not have imogen. >>> daniel: disease carrying ticks are just about everywhere. ticks that spread lyme disease now live in half of all u.s. counties. that's up from just 30% of counties back in the late '90s the cdc says it is important to be aware that ticks could be living in places where they were not previously. since the '90s the number of than tripled. >> julie: taking look at roads at 9:46 on tuesday, still slow on the expressway furnace brook parkway to columbia road. 93 south sluggish starting right after the cloverleaf and continuing through woburn, through medford and then as you approach somerville. zakim bridge and leverett connector pretty typical delays right now. over to those live drive times, 20 minutes on route 1 from 128 to the tobin, 45 minutes on 93 south from 495 to the leverett connector and 37 minutes on 128 south from route 1 in peabody to the weston tolls. meteorologist jason brewer in for shiri spear

you see what happens to the start -- in particular, biogenic, that blue line.nvestors don't want the association. binky: two or three points we make. it is important to remember we are talking about the equity market and the equity markets tended to price things in quickly. by back announcements on average are associated with outperformance and that is a very quick outperformance. and then there is a separation where overtime there is a whole set of firms that will basically get a associated with the buybacks. you mentioned some companies .hat are high-growth companies not necessarily associated with outperformance of the buybacks. alix: great stuff. such a pleasure to have you here. binky: my pleasure. scarlet: coming up, will catalog attempt to split from spain? ♪ alix: i am alix steel. "what'd you miss?" spain sites to remain unified. are fighting to split from the country. toning us is erik nielsen give more perspective on the bond selloff and the concerns in catalonia. what do you see happening here? how does this wind up playing out? erik: there is differ

. >>> biogen a nice gainer, guidance in line, 4.50, beat 4.08.you have more on the internals -- >> my travel trust owns biogen. we felt the ceo -- not that they were sandbagging, but they got ahead of themselves. i remember when the stock was in the 400s, everybody felt they were about to cure the terrible disease that's alzheimer's. they basically said, listen, whoa, we have to rein in the street. they reined in the street in a way that they could beat it. there was an extra week last year, they still beat the numbers. so they had been conservative. against that i will tell that you this group has become hellish because hillary clinton may, for all i know, bernie sanders, hillary clinton, senator cruz and donald trump may see this biogen increase and it could set them off. they'll all go to twitter and say what a ripoff. these stocks are trading on tweets from presidential -- >> yeah. >> you know, between inversions and drug prices, and martin shkreli -- >> shkreli. >> is he in congress now. >> he's not in jail, right? he's out on bail? >> he's

. >>> biogen beat earnings targets because of strong sales of its oral multiple sclerosis drug. the 2016 outlook was in line with estimates. shares up 5% to 273.26. >>> tupperware cited a weeker global economy and strong dollar for a worse than expected sales drop and an earnings miss. the maker of household storage products gets more than 70% of its revenue outside the united states. as a result, taupperware battle what it calls economic and political headwinds. shares fell nearly 15% to 4397. >>> health insurer anthem said its profit fell in the quarter, weighed down by costs of the affordable care act plans. the company said it had momentum heading into 2016 with more people enrolling in its medicaid plans and it would be helped by the pending acquisition of cigna. shares of anthem were off about 5%. >>> norfolk southern said that its profit fell 30% on lower freight volumes. coal, in particular. the railroad also said it will shed 1,200 jobs this year. as part of a five-year cost cutting plan. the move comes as norfolk southern tries to fend off a $28 million takeover bid fr

. >> reporter: that prompted her to earn funding from a tech giant, biogen. when she wants something, she requested it. one small grant request from google turned into more. >> i asked for $2500 and they gave me $2500 more. but they gave $5000 to me. but they gave money to the entiti state, students with disabilities. for the grants on the -- side. >> reporter: she won't take credit for the extra $95,000, always deferring praise. she says everyone plays a role in her education model, especially the students. >> i tell them there is one four letter school that i want their ears pick up and i say it's work. >> reporter: it's the team approach, and joanne blumenfeld's team is winning. in raleigh with our teacher of the week, gerald owens, wral >> there is a tv character who used to say work! and when he would say that his voice which shoot up two octaves. >> that's what the kids say. work! >>> we've got snow later today, probably not going to be widespread across the region but there could be flurries or couple of snow showers later on. here's a look at the life

abigail: biogenic on one of the big winners at the nasdaq at the open.great fourth quarter, beating estimates. they made $4.50, up 20% from last year. they had a record quarter, but were really stands out -- but what really stands out is that the management team was at the health conference recently, giving cautious commentary and it appears to have sandbagged and the stock is up big today. it is still down about 40% from last year's peak. david: thank you. "bloomberg ," does the fed risk being humiliated by markets of the raise rates again? ♪ welcome back. here is your latest business flash. european union says auto emission tests test should be tougher. proposals are a reaction to volkswagen's cheating scandal. they went independent testing and more screening on roads instead of labs. members of the european parliament will debate the changes. their debt is dropping the plan to merge. were going to buy them from $4.6 million and media general owns tv stations. stanford beats hybrid in the donation race. stanford took in a record $1.6 billion. harva

if you want to give biogen that was upgraded. it's not that expensive. i like amgen. and then let's put gilead in that mix. those are high cross stocks. they do better. i'm not as concerned or negative as most of the people although it did rally today. all right. sometimes the market wants to go lower. we have to accept that. when it gets this negative i am urging actually calm. i want you to consider even as the market goes lower picking a favorite stock that's now at your price. all right on "mad money" tonight i already examined the winners and losers in 2015. tonight i'm eyeing the nasdaq. could the crash in crude continue? mr. wonderful himself. kevin o'leary can brighten up a little bit of sunshine in the show. stick with cramer. >> you're out of your mind putting a $10 million value on this. >> don't miss a second of "mad money." have a question, tweet cramer. #"mad tweets." send jim an e-mail to madmoney@cnbc.com or give us a head to madmoney.cnbc.com. >> i am urging you to remember that stocks can go up too. it's in this difficult environment that you need to

performers, the top performer is biogen.tech giant put up a great fourth quarter on the strength multiple sclerosis drug. the company beat estimates by 10%. but what stands out is just a couple of weeks ago, the company was giving cautious commentary. they sandbagged the street to produce an upside surprise. on that strength, the stock is up about 40% from its record week last year. lots of big selling momentum to overcome. plus you have the biotech index still in a bear market. david: thank you so much. abigail mentioning the negative macro economic guidance we got yesterday. still wondering if apple is ringing the bell about something bigger. a lot of concern about what is going on in china. alix: not only apple, but boeing taking points off the dow. definitely some more questions. facebook is the world most popular social media site. the company reports earnings after the bell. the company is gaining more users. joining us is cory johnson. we heard barry diller a few moments ago saying facebook has enough users to satisfy

maybe bio jen -- biogen.hen there are other companies that need to do a deal, said they are doing a deal, such as johnson & johnson. that could work. at the numbers on paper could work, but the reality is, china's advantage is having -- scheier's advantage is having its lower earnings applied to baxalta. mark: is it about expanding the global reach for shire? shire is a big player in one sector. this gives it a potentially strong leg in another rare disease area which is him a few you. it's difficult to see a specific can go or asset shire after that is a perfect fit. is rare diseases gives them a perfect fit. leadershipaxalta's in hemophilia is being challenged. sam: yes, they are coming up with products in this year and 2017 that will potentially compete. shire could get from this deal could be -- the aunt 2017, consensus estimates are a little lighter for baxalta . the reality is there could be challenges there. hasshire, i'm assuming, done its homework and is looking and thinking they would be able to use

ceoad the biogenic yesterday we talked about their own trials on expendable treatments for alzheimer's --itical is experimental treatments for all timers. how critical is it that you have success, and what if the program underperforms -- how critical is for eli lilly? mr. lechleiter: one significant accompaniment is data on our psoriasis drug, positive outcome data for our diabetes drug. i think investors see eli lilly has more than a one-trick pony. it is not all writing on alzheimer's. having said that, we have the most extensive investment in alzheimer's than anyone in the industry. phase-three drug. we should get a read on that study by the end of the year. as we explained to investors last year, we have many molecules behind that that work target, anda boyd also on another culprit in alzheimer's disease. betty: john, i know you sell your drugs all over the world. i am curious if what is going on in china will have an impact on you. mr. lechleiter: our exposure in china is fairly limited. although our business had been growing quite robustly until last year, when i think things slo

not being led by the biotech index with the mbi down even to the nasdaq largely on strength out of biogeningfourth quarter estimates. the company made $4.50 per share up 20% year-over-year as its top ms drug had a record quarter. the management just a few weeks ago at the jpmorgan health care conference gave cautious comments. in a way they sandbagged the street. we have the stock surging today but still down about 40% from its peak last year. off on aares are boston globe report that the massachusetts attorney general says gilead may face legal action unless it lowers the pricing on its hepatitis b drugs. betty: thank you so much. abigail doolittle, live at the nasdaq. biotech drugs, fourth-quarter earnings missing estimates. revenue plunged in its alcon eye care unit. the company's new or drugs and pipeline. mark: here is what the chief executive told us on bloomberg about demand for its new drug. >> if you look at the innovation machine novartis is in the pharmaceutical division, we have generated a number of new medicines that are growing significantly. parte offsetting a large of tha

biogen this morning looks like it will be doing that. up 6% after they put out their fourth quarter results. beating eps and coming in short on revenue. sorry beating on revenue as well. what people are watching is their guidance for the year. they bracketed what the street was expecting so you're seeing the stock go up this morning. people are nervous about the health of their multiple sclerosis franchise. that one beat expectations. people pretty happy with biogen hoping that continues throughout biotech the stock trading up. novartis, much bigger european company. that coming in under expectations. company really trying to restructure it's eye care business. that's a big thing for them. this year they will face generic competition to their leukemia drug and than heart failure drug that they are just launching. those are things people are watching with novartis but stock is trading down after the fourth quarter numbers. >> meg, thank you very much. when we come back will apple set the stage for today's trading session. we'll talk about

the high growth organic and natural food stocks we discuss on the show, or biotech names like biogen, the four horsemen. the companies growing like drug companies of old when big pharma was synonymous with growth. how do you analyze? judge? how do you know what grows well? when we buy a stock, we pay for a company's future earnings per share. we have to learn the basic all investing. the way we arrive at the real cost of the stock, not just the dollar cost. we understand this because we have to compare stocks on apples to apples basis, not just texaco worth $90 other coca-cola is worth $40. apple's not worth less after a split, is it? let's go over what a stock price really means. here's the simple algebra. the share price, the p, the pe ratio, shorthand for valuing stocks, the p equals the e times what's known as the multiple or m. e times m equals p. solve for m, what we're going to pay for the earnings stream. what's the multiple we're going to pay? the price earnings multiple is the key telling us what investors fork over for a company's future earnings, and the most important det

. >> biogen beats on the top and bottom line. an 8% rise in sales.hat's a nice gain. >> you look at this actually loes closer to 7.5%. let's not argue about that. up almost 6% as well. you look at this company and where they're making some strength it's obviously ms but look at the pipeline as well alzheimer's. two in phase three. a lot going on at this company. it seems very cheap. >> boeing is one of the biggest drags on the dow today. >> it is. the reversal in terms of the fundamental story. we talk about and we have this argument focussing on technicals and fundamentals but when the fundamentals change as much as they have changed for boeing you have to address the situation and look at your holdings and pair back on them. >> coming up a round-robin. our experts will take their positions on those stocks ahead of the earnings tonight plus it's cheaper to fill your tank in houston than abu dhabi right now. can oil go much lower though? we'll ask citigroup's global head of commodities research. we're back after this. we were born 100 years ago into

and good numbers from biogen as well. >> it's hardly moving. >> although, you know, when you have sentiment like this, and for three or information years, a giant swing, the pendulum doesn't stop when it goes back to fair value, it keeps going. i think we have a ways to go before you see the bottom. >> huge eps beat. decent revenue beat. most of their drugs much better than expected. guidance for next year i thought was really good. if biotech was in favor, which it's clearly not, this stock would be up 4.5%, 5%. it hasn't even gotten back the losses from today. to karen's point, the pendulum swings, it swings now the wrong way. you need ibb, in my opinion, to get back up above 285 before you can start to look at this, unfortunate unfortunately. >> now it seems like, i don't want to say politicians, but politicians, lawmakers, whoever, they're glomming on at this point in terms of the drug price battle. >> that's the problem. even with the good ones, the earnings are in question. not because the company's not going to hit it, but you just don't know politically are they going to be able to

cambridge-based biogen for a generic version for a rheumatoid arthritis. created a replica of a drug embrol which is made by a plant in rhode island. they allow the sale of these replica drugs known as bio similar. the patent for embrol runs through 2028. >>> disease-carrying ticks are just about everywhere. a new study from the cdc say ticks that spread lyme disease live in half of u.s. countries up from 30% of countries in the late 90s. important to be 'ware that kicks can be living in place is where they were. no previously. the number of lyme disease cases have tripled. >>> your iphone can give your doctor important information without you leaving hope, a new app can beam from your bathroom scale to your doctor's office and being israel medical center. hoping to lead to a new kind of remote health care that can drive down costs or prevent or manage disease. >>> anthropology is getting -- anthropolgie is getting headache for selling this can. when i say it is on sale, originally $148. people were writing reviews saying ridiculous to spend $1 saying ridi

alix: that was the ceo of biogen earlier today on bloomberg markets.st names are meeting in the ideas come looking for fresh opportunities at j.p. morgan's health care conference. as we have been reporting, are seeing their worst start to the year since 2001. what has the sector spooked? let's ask drew armstrong. this anything more than profit-taking after years of the propping upsector the market? drew: one thing we did was jpmorgan mother their health care conference is the big investor meeting, it kicks off every year, all of wall street flies out there. we looked at what was the first day of trading -- this is the worst start in 15 years. what we've seen happening is some of what you're talking about -- biotech stocks have done great, health care stocks have been great. the gains have outpaced the broader market, but there's been concerns. was just talking about drug prices. in major concern. can these gains continue? can the market continued to rise? no, it is due for a correction. alix: there is a distinction between technically the stocks versus

. >> to be fair, while celgene is down more, biogen and amgen, two of the other larger biotechnologyif you will, are also down 9%. >> multiple shrinkage. as soon as you hear that, you think about costanza, but people are fleeing this group. the speculative ones -- i think this jpmorgan healthcare conference is going very well. a lot of the biotechs are doing well. but this is that -- people think they're risky and selling risky stocks. amgen is inexpensive. inexpensive stock. i'm intrigued. i'm intrigued with celgene but disheartened to see bob step up to executive chairman. you want him at the helm. he has a deep bench. i'm sure he's right, which is why i think celgene is a buy. if t the jpmorgan is usually a time you want to buy stocks. >> the guidance from anthem and aetna not bad. >> no. balance that against mckesson which is horrendous. rite-aid, maybe losing that contract. >> the three big gainers on the dow, intel, coke and apple are all upgrade related. you already covered the intel call. stifel takes coke to a buy. >> i think coke is doing well. i do. people just say, well,

ceo onthe biogen yesterday, who talk about their own trials. critical is it that you have success in this treatment? what is the program -- what if the program underperforms? >> one significant accomplishment in 2015 is we rheumatoid on our arthritis drug. we had some positive outcomes data for art diabetes drug. -- our diabetes drug. investors see lily as more than a one trick pony. it is not all writing on alzheimer's. we have the most extensive investment in alzheimer's of anyone in the industry. phasely the drug in three, we should get a read on that study by the end of the tor, but as we explained investors late last year, we have other molecules behind that network on that amyloid target -- that work on that amyloid target and another culprit in alzheimer's disease. alix: you sell your drugs all over the world. i'm curious if what's going on in china has had an impact on you. >> our exposure in china is fairly limited. our business had been growing quite robustly up until last year when things slowed down for everyone. we taka very long-t

. >> i go biogen, but i answer to either. > so bob kelly has a question for you.ean, on my way in, where r very frustrating that we had 12 inches of snow at times and the couple of plow trucks that i saw were all parked off to the side. i know the guys got to take a break, but you would think that the schuylkill would at least have a lane cleared since it's a major road into philadelphia. why would you hit gene with this at 6:42. >> because you asked me to. bob, i could tell you hour 450 trucks are out on the highway. one or two may have pulled off to the side, maybe a mechanical issue. it's something i would have to look into it. i can't answer that right at this very moment, it's something that i could look. my initial thought would be either mechanical or one of the problems the drivers are having with the visibility and with the blowing snow and possibly had to clear the windshield. > i get it. it's just frustrating. i'm just telling you i'm frustrated. i'm one of the guys and that's the feedback we get here at fox on both our e-mails and facebook and twitter.

biogen won approval to sell generic version of rheumatoid arthritis drug. it has created near replica at embren. they allow biosimilars and u.s. does not and patent for embren. >>> gene: new study shows rather now live in half of u.s. counties, up 30% of counties back in the late '90s and important to be aware ticks could be living in places where they were not previously since the '90s the number of tick -- number of lyme disease cases have more than tripled. >> sara: incredible new technology could be the new way to study brain injuries. revenuers have implanted chips that have tiny electronic sensors in the brains of rats. those chips melt away once they are no longer needed. scientists hope such sensors could eliminate the need for large bulky systems to monitor brain injuries for people. researchers hope to do trial of implant on humans and that's still a few years away. >>> sara: catching up on sleep may help reduce diabetes. university of chicago found getting fewer than five hours of sleep on four consecutive nights diabetes risk by 16% and after fo

with biogen, some stuff people are very focused on.you look at names like gilead, or sell jean, which created 12% growth, you're going to be well positioned. il stuff, the china stuff certainly is not impacting whatever is going on on alzheimer's. >> yeah. well, that's a point. but also not helping out there in the space. thanks a lot for joining us. >> absolutely. >> mike there from rbc capital markets. we've got more breaking news on gopro. let's get back to josh lipton. >> well, kelly, so we had this news from gopro preannouncing q4 results that were a disappointment. i now have a letter from gopro's ceo nick woodman to his employees. he's talking about how gopro has also beginning to reduce head count by about 7% across various divisions of the company. saying this was a difficult decision. a deeply emotional one. but necessary, he says, for the greater good of gopro. he also talked about the reasons for that difficult 2015. gopro, remember, announced it was initially mispriced. crippling demand initially. gopro then cut the price

. >> how about this, biogen, that's the leading stock of all the of the s&p 500, higher demand for theup 4 1/2%. not bad. later this hour, headline from congressman louie gohmert who is on the show. why hillary clinton is backing president obama's agenda, because she wants to avoid indictment. the zika virus is spreading and is here, a lot of people are very worried. it's only wednesday and the week is shaping up as a disaster for the president, very bad news on the debt and obamacare. i guess we're all focusing on tomorrow's debate or next week's iowa caucus, what a shame, this is about your money and the obama legacy. bad news on both counts. you can't ignore this. first, the red ink on debt. we learned monday it has become a gusher. we will have to borrow well over a half trillion dollars this year and a whole lot more every year in the future. what's the problem? same as usual, run away government spending. the left led by president obama is buying votes with your money and charging it on the charge card. massive run away debt is a rotten legacy. this week we find out how bad it is

a lot of big biotech names like biogen trading lower. the worst performing sector is technology down about 3%. >> dom is over here, $2 billion to buy into the close but what does that tell you? >> in case somebody missed it because of the expiration program we're seeing you could see a billion in buy interest in the close evaporate in an instant. keep all of that in mind when you hear the big numbers. >> we have our friend david darcy and matt from financial. let me start with you, you're following this market minute by minute, it's an options expiration. what do you expects to happen in the next five to ten minutes. >> a billion won't get you what it did a little while ago. we're not going to get a rally. >> 2 billion. >> so we're not going to get a rally until the end of the day. we're not seeing anything. the other day we saw incredible short interest. that's still at work here and there's no recovering that yext they are not going to cover on expiration friday, not in the long weekend here, too much out there. >> any more optimistic

cambridge-based biogen for a generic version for a rheumatoid arthritis. created a replica of a drug embrol which is made by a plant in rhode island. they allow the sale of these replica drugs known as bio similar. the patent for embrol runs through 2028.